Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 7804-7820

  Basudhar, Debashree ^a   Bharadwaj, Gaurav ^a   Cheng, Robert Y ^b   Jain, Sarthak ^c   Shi, Sa ^d,e   Heinecke, Julie L ^b   Holland, Ryan J ^f   Ridnour, Lisa A ^b   Caceres, Viviane M ^d,g   Spadari Bratfisch, Regina C ^g   Paolocci, Nazareno ^d,h   Velázquez Martínez, Carlos A ^c   Wink, David A ^b   Miranda, Katrina M ^a  

^a University of Arizona   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f NATIONAL CANCER INSTITUTE   (United States)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; DIAZENIUMDIOLATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NITROXYLNITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG DECOMPOSITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART MUSCLE CELL; LUNG NON SMALL CELL CANCER; NONHUMAN; SARCOMERE LENGTH; STOMACH ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; AZO COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; ENZYME INHIBITORS; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; NITRIC OXIDE; NITROGEN OXIDES; PRODRUGS; SARCOMERES;

EID: 84886468693     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400196q     Document Type: Article

References (96)

1. Wallace, J. L. Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn't the stomach digest itself? Physiol. Rev. 2008, 88, 1547-1565
2. Luscher, T. F.; Boulanger, C. M.; Dohi, Y.; Yang, Z. H. Endothelium-derived contracting factors Hypertension 1992, 19, 117-130
3. Davidge, S. T. Prostaglandin H synthase and vascular function Circ. Res. 2001, 89, 650-660
4. Cheng, Y.; Austin, S. C.; Rocca, B.; Koller, B. H.; Coffman, T. M.; Grosser, T.; Lawson, J. A.; FitzGerald, G. A. Role of Prostacyclin in the cardiovascular response to thromboxane A(2) Science 2002, 296, 539-541
5. Breyer, M. D.; Breyer, R. M. Prostaglandin-E receptors and the kidney Am. J. Physiol. 2000, 279, F12-F23
6. Cao, C. Y.; Matsumura, K.; Yamagata, K.; Watanabe, Y. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain Am. J. Physiol. 1997, 272, R1712-R1725
7. Kiyoshi, M.; Chunyu, C. A. O.; Yasuyoshi, W. Possible role of cyclooxygenase-2 in the brain vasculature in febrile response Ann. N.Y. Acad. Sci. 1997, 813, 302-306
8. Kawaguchi, H.; Pilbeam, C. C.; Harrison, J. R.; Raisz, L. G. The role of prostaglandins in the regulation of bone metabolism Clin. Orthop. Relat. Res. 1995, 313, 36-46
9. Dubois, R. N.; Abramson, S. B.; Crofford, L.; Gupta, R. A.; Simon, L. S.; Van De Putte, L. B.; Lipsky, P. E. Cyclooxygenase in biology and disease FASEB J. 1998, 12, 1063-1067
10. Cimino, P. J.; Keene, C. D.; Breyer, R. M.; Montine, K. S.; Montine, T. J. Therapeutic targets in prostaglandin E2 signaling for neurologic disease Curr. Med. Chem. 2008, 15, 1863-1869
11. Hein, A. M.; O'Banion, M. K. Neuroinflammation and memory: The role of prostaglandins Mol. Neurobiol. 2009, 40, 15-32
12. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases J. Neuropathol. Exp. Neurol. 2004, 63, 901-910
13. Kamei, D.; Murakami, M.; Nakatani, Y.; Ishikawa, Y.; Ishii, T.; Kudo, I. Potential role of microsomal postaglandin E synthase-1 in tumorigenesis J. Biol. Chem. 2003, 278, 19396-19405
14. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nature, New Biol. 1971, 231, 232-235
15. Wallace, J. L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years Gastroenterology 1997, 112, 1000-1016
16. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017
17. Mitchell, J. A.; Warner, T. D. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs Nat. Rev. Drug Discovery 2006, 5, 75-78
18. Everts, B.; Währborg, P.; Hedner, T. COX-2-specific inhibitors-the emergence of a new class of analgesic and anti-inflammatory drugs Clin. Rheumatol. 2000, 19, 331-343
19. Antman, E. M.; Bennett, J. S.; Daugherty, A.; Furberg, C.; Roberts, H.; Taubert, K. A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: A scientific statement from the American Heart Association Circulation 2007, 115, 1634-1642
20. Keeble, J. E.; Moore, P. K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs Br. J. Pharmacol. 2002, 137, 295-310
21. Flaherty, J. T.; Reid, P. R.; Kelly, D. T.; Taylor, D. R.; Weisfeldt, M. L.; Pitt, B. Intravenous nitroglycerin in acute myocardial-infarction Circulation 1975, 51, 132-139
22. Rigas, B.; Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention Trends Mol. Med. 2004, 10, 324-330
23. Minamiyama, Y.; Takemura, S.; Nishino, Y.; Okada, S. Organic nitrate tolerance is induced by degradation of some cytochrome P450 isoforms Redox Rep. 2002, 7, 339-342
24. Thatcher, G. R. J. NO problem for nitroglycerin: Organic nitrate chemistry and therapy Chem. Soc. Rev. 1998, 27, 331-337
25. TorfgaÌŠrd, K. E.; Ahlner, J. Mechanisms of action of nitrates Cardiovasc. Drugs Ther. 1994, 8, 701-717
26. Hulsman, N.; Medema, J. P.; Bos, C.; Jongejan, A.; Leurs, R.; Smit, M. J.; de Esch, I. J. P.; Richel, D.; Wijtmans, M. Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin J. Med. Chem. 2007, 50, 2424-2431
27. Velázquez, C.; Rao, P. N. P.; Knaus, E. E. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: Design, synthesis, biological evaluation, and nitric oxide release studies J. Med. Chem. 2005, 48, 4061-4067
28. 2-Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies Bioorg. Med. Chem. 2007, 15, 4767-4774
29. Maragos, C. M.; Morley, D.; Wink, D. A.; Dunams, T. M.; Saavedra, J. E.; Hoffman, A.; Bove, A. A.; Isaac, L.; Hrabie, J. A.; Keefer, L. K. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide-vasorelaxant effects J. Med. Chem. 1991, 34, 3242-3247
30. Keefer, L. K. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): Emerging commercial opportunities Curr. Top. Med. Chem. 2005, 5, 625-634
31. Dutton, A. S.; Fukuto, J. M.; Houk, K. N. Mechanisms of HNO and NO production from Angeli's salt: Density functional and CBS-QB3 theory predictions J. Am. Chem. Soc. 2004, 126, 3795-3800
32. Dutton, A. S.; Suhrada, C. P.; Miranda, K. M.; Wink, D. A.; Fukuto, J. M.; Houk, K. N. Mechanism of pH-dependent decomposition of monoalkylamine diazeniumdiolates to form HNO and NO, deduced from the model compound methylamine diazeniumdiolate, density functional theory, and CBS-QB3 calculations Inorg. Chem. 2006, 45, 2448-2456
33. Salmon, D. J.; Torres de Holding, C. L.; Thomas, L.; Peterson, K. V.; Goodman, G. P.; Saavedra, J. E.; Srinivasan, A.; Davies, K. M.; Keefer, L. K.; Miranda, K. M. HNO and NO release from a arimary amine-based diazeniumdiolate as a function of pH Inorg. Chem. 2011, 50, 3262-3270
34. - in failing hearts: Independence from β-adrenergic signaling Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5537-5542
35. Paolocci, N.; Saavedra, W. F.; Miranda, K. M.; Martignani, C.; Isoda, T.; Hare, J. M.; Espey, M. G.; Fukuto, J. M.; Feelisch, M.; Wink, D. A.; Kass, D. A. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10463-10468
36. Norris, A. J.; Sartippour, M. R.; Lu, M.; Park, T.; Rao, J. Y.; Jackson, M. I.; Fukuto, J. M.; Brooks, M. N. Nitroxyl inhibits breast tumor growth and angiogenesis Int. J. Cancer. 2008, 122, 1905-1910
37. Nagasawa, H. T.; Kawle, S. P.; Elberling, J. A.; Demaster, E. G.; Fukuto, J. M. Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-a-vis vascular smooth-muscle relaxants J. Med. Chem. 1995, 38, 1865-1871
38. Saavedra, J. E.; Bohle, D. S.; Smith, K. N.; George, C.; Deschamps, J. R.; Parrish, D.; Ivanic, J.; Wang, Y. N.; Citro, M. L.; Keefer, L. K. Chemistry of the diazeniumdiolates. O- versus N-alkylation of the RNH[N(O)NO](-) ion J. Am. Chem. Soc. 2004, 126, 12880-12887
39. Andrei, D.; Salmon, D. J.; Donzelli, S.; Wahab, A.; Klose, J. R.; Citro, M. L.; Saavedra, J. E.; Wink, D. A.; Miranda, K. M.; Keefer, L. K. Dual mechanisms of HNO generation by a nitroxyl prodrug of the diazeniumdiolate (NONOate) class J. Am. Chem. Soc. 2010, 132, 16526-16532
40. Saavedra, J. E.; Shami, P. J.; Wang, L. Y.; Davies, K. M.; Booth, M. N.; Citro, M. L.; Keefer, L. K. Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: In vitro antileukemic activity J. Med. Chem. 2000, 43, 261-269
41. Tang, X.; Xian, M.; Trikha, M.; Honn, K. V.; Wang, P. G. Synthesis of peptide-diazeniumdiolate conjugates: Towards enzyme activated antitumor agents Tetrahedron Lett. 2001, 42, 2625-2629
42. Shafirovich, V.; Lymar, S. V. Nitroxyl and its anion in aqueous solutions: Spin states, protic equilibria, and reactivities toward oxygen and nitric oxide Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7340-7345
43. Miranda, K. M.; Katori, T.; Torres de Holding, C. L.; Thomas, L.; Ridnour, L. A.; McLendon, W. J.; Cologna, S. M.; Dutton, A. S.; Champion, H. C.; Mancardi, D.; Tocchetti, C. G.; Saavedra, J. E.; Keefer, L. K.; Houk, K. N.; Fukuto, J. M.; Kass, D. A.; Paolocci, N.; Wink, D. A. Comparison of the NO and HNO donating properties of diazeniumdiolates: Primary amine adducts release HNO in vivo J. Med. Chem. 2005, 48, 8220-8228
44. Andersen, H. J.; Skibsted, L. H. Kinetics and mechanism of thermal-oxidation and photooxidation of nitrosylmyoglobin in aqueous solution J. Agric. Food Chem. 1992, 40, 1741-1750
45. Doyle, M. P.; Pickering, R. A.; Cook, B. R. Oxidation of oxymyoglobin by nitric oxide through dissociation from cobalt nitrosyls J. Inorg. Biochem. 1983, 19, 329-338
46. Doyle, M. P.; Hoekstra, J. W. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins J. Inorg. Biochem. 1981, 14, 351-358
47. Miranda, K. M.; Paolocci, N.; Katori, T.; Thomas, D. D.; Ford, E.; Bartberger, M. D.; Espey, M. G.; Kass, D. A.; Feelisch, M.; Fukuto, J. M.; Wink, D. A. A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9196-9201
48. Pryor, W. A.; Church, D. F.; Govindan, C. K.; Crank, G. Oxidation of thiols by nitric oxide and nitrogen dioxide-synthetic utility and toxicological implications J. Org. Chem. 1982, 47, 156-159
49. Tang, J.; Faustman, C.; Lee, S.; Hoagland, T. A. Effect of glutathione on oxymyoglobin oxidation J. Agric. Food Chem. 2003, 51, 1691-1695
50. Wink, D. A.; Feelisch, M.; Fukuto, J.; Chistodoulou, D.; Jourd'heuil, D.; Grisham, M. B.; Vodovotz, Y.; Cook, J. A.; Krishna, M.; DeGraff, W. G.; Kim, S.; Gamson, J.; Mitchell, J. B. The cytotoxicity of nitroxyl: Possible implications for the pathophysiological role of NO Arch. Biochem. Biophys. 1998, 351, 66-74
51. Kojima, H.; Sakurai, K.; Kikuchi, K.; Kawahara, S.; Kirino, Y.; Nagoshi, H.; Hirata, Y.; Nagano, T. Development of a fluorescent indicator for nitric oxide based on the fluorescein chromophore Chem. Pharm. Bull. 1998, 46, 373-375
52. Espey, M. G.; Miranda, K. M.; Thomas, D. D.; Wink, D. A. Ingress and reactive chemistry of nitroxyl-derived species within human cells Free Radical Biol. Med. 2002, 33, 827-834
53. Davies, N. M.; Sharkey, K. A.; Asfaha, S.; Macnaughton, W. K.; Wallace, J. L. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rat Aliment. Pharmacol. Ther. 1997, 11, 1101-1108
54. Huang, M.; Stolina, M.; Sharma, S.; Mao, J. T.; Zhu, L.; Miller, P. W.; Wollman, J.; Herschman, H.; Dubinett, S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production Cancer Res. 1998, 58, 1208-1216
55. Williams, C. S.; Smalley, W.; DuBois, R. N. Aspirin use and potential mechanisms for colorectal cancer preventionn J. Clin. Invest. 1997, 100, 1325-1329
56. Rouzer, C. A.; Marnett, L. J. Cyclooxygenases: Structural and functional insights J. Lipid Res. 2009, 50, S29-S34
57. Kennedy, T. A.; Smith, C. J.; Marnett, L. J. Investigation of the role of cysteines in catalysis by prostaglandin endoperoxide synthase J. Biol. Chem. 1994, 269, 27357-27364
58. Lopez, B. E.; Rodriguez, C. E.; Pribadi, M.; Cook, N. M.; Shinyashiki, M.; Fukuto, J. M. Inhibition of yeast glycolysis by nitroxyl (HNO): A mechanism of HNO toxicity and implications to HNO biology Arch. Biochem. Biophys. 2005, 442, 140-148
59. Lopez, B. E.; Wink, D. A.; Fukuto, J. M. The inhibition of glyceraldehyde-3-phosphate dehydrogenase by nitroxyl (HNO) Arch. Biochem. Biophys. 2007, 465, 430-436
60. Shen, B.; English, A. M. Mass spectrometric analysis of nitroxyl-mediated protein modification: Comparison of products formed with free and protein-based cysteines Biochemistry 2005, 44, 14030-14044
61. Schreinemachers, D. M.; Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study Epidemiology 1994, 5, 138-146
62. Harris, R. E.; Beebe-Donk, J.; Doss, H.; Doss, D. B. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review) Oncol. Rep. 2005, 13, 559-583
63. Fosslien, E. Molecular pathology of cyclooxygenase-2 in neoplasia Ann. Clin. Lab. Sci. 2000, 30, 3-21
64. Howe, L. R.; Subbaramaiah, K.; Brown, A. M.; Dannenberg, A. J. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer Endocr.-Relat. Cancer 2001, 8, 97-114
65. Pai, R.; Nakamura, T.; Moon, W. S.; Tarnawski, A. S. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors FASEB J. 2003, 17, 1640-1647
66. Fulton, A. M.; Zhang, S. Z.; Chong, Y. C. Role of the prostaglandin E2 receptor in mammary tumor metastasis Cancer Res. 1991, 51, 2047-2050
67. Wang, D.; DuBois, R. N. The role of COX-2 in intestinal inflammation and colorectal cancer Oncogene 2009, 29, 781-788
68. Trifan, O. C.; Hla, T. J. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis Cell. Mol. Biol. 2003, 7, 207-222
69. Leahy, K. M.; Koki, A. T.; Masferrer, J. L. Role of cyclooxygenases in angiogenesis Curr. Med. Chem. 2000, 7, 1163-1170
70. Ruegg, C.; Dormond, O.; Mariotti, A. Endothelial cell integrins and COX-2: Mediators and therapeutic targets of tumor angiogenesis Biochim. Biophys. Acta, Rev. Cancer 2004, 1654, 51-67
71. Gately, S. The contributions of cyclooxygenase-2 to tumor angiogenesis Cancer Metastasis Rev. 2000, 19, 19-27
72. Harris, S. G.; Padilla, J.; Koumas, L.; Ray, D.; Phipps, R. P. Prostaglandins as modulators of immunity Trends Immunol. 2002, 23, 144-150
73. Wilson, K. T.; Fu, S.; Ramanujam, K. S.; Meltzer, S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res. 1998, 58, 2929-2934
74. Chiarugi, V.; Magnelli, L.; Gallo, O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis Int. J. Mol. Med. 1998, 2, 715-719
75. Mocellin, S.; Bronte, V.; Nitti, D. Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities Med. Res. Rev. 2007, 27, 317-352
76. Stoyanovsky, D. A.; Schor, N. F.; Nylander, K. D.; Salama, G. Effects of pH on the cytotoxicity of sodium trioxodinitrate (Angeli's salt) J. Med. Chem. 2004, 47, 210-217
77. Nath, N.; Vassell, R.; Chattopadhyay, M.; Kogan, M.; Kashfi, K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: Effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling Biochem. Pharmacol. 2009, 78, 1298-1304
78. Hockel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 2001, 93, 266-276
79. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2007, 4, 891-899
80. Gatenby, R. A.; Gillies, R. J. Glycolysis in cancer: A potential target for therapy Int. J. Biochem. Cell Biol. 2007, 39, 1358-1366
81. Sirover, M. A. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells J. Cell. Biochem. 2005, 95, 45-52
82. Colell, A.; Green, D. R.; Ricci, J. E. Novel roles for GAPDH in cell death and carcinogenesis Cell Death Differ. 2009, 16, 1573-1581
83. Catella-Lawson, F.; Reilly, M. P.; Kapoor, S. C.; Cucchiara, A. J.; DeMarco, S.; Tournier, B.; Vyas, S. N.; FitzGerald, G. A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N. Engl. J. Med. 2001, 345, 1809-1817
84. Fosbol, E. L.; Folke, F.; Jacobsen, S.; Rasmussen, J. N.; Sorensen, R.; Schramm, T. K.; Andersen, S. S.; Rasmussen, S.; Poulsen, H. E.; Kober, L.; Torp-Pedersen, C.; Gislason, G. H. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals Circ.: Cardiovasc. Qual. Outcomes 2010, 3, 395-403
85. Ma, X. L.; Gao, F.; Liu, G. L.; Lopez, B. L.; Christopher, T. A.; Fukuto, J. M.; Wink, D. A.; Feelisch, M. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14617-14622
86. 2+ cycling Circ. Res. 2007, 100, 96-104
87. Froehlich, J. P.; Mahaney, J. E.; Keceli, G.; Pavlos, C. M.; Goldstein, R.; Redwood, A. J.; Sumbilla, C.; Lee, D. I.; Tocchetti, C. G.; Kass, D. A.; Paolocci, N.; Toscano, J. P. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl Biochemistry 2008, 47, 13150-13152
88. 2+ transients by exclusively targeting SR Ca2+-cycling Front. Biosci. 2010, 2, 614-626
89. Drago, R. S.; Karstetter, B. R. The reaction of nitrogen(II) oxide with various primary and secondary amines J. Am. Chem. Soc. 1961, 83, 1819-1822
90. Lopez, B. E.; Shinyashiki, M.; Han, T. H.; Fukuto, J. M. Antioxidant actions of nitroxyl (HNO) Free Radical Biol. Med. 2007, 42, 482-491
91. Miranda, K. M.; Nagasawa, H. T.; Toscano, J. P. Donors of HNO Curr. Top. Med. Chem. 2005, 5, 649-664
92. Doyle, M. P.; Mahapatro, S. N. Nitric-oxide dissociation from trioxodinitrate(II) in aqueous solution J. Am. Chem. Soc. 1984, 106, 3678-3679
93. Kojima, H.; Nakatsubo, N.; Kikuchi, K.; Kawahara, S.; Kirino, Y.; Nagoshi, H.; Hirata, Y.; Nagano, T. Detection and imaging of nitric oxide with novel fluorescent indicators: Diaminofluoresceins Anal. Chem. 1998, 70, 2446-2453
94. Winter, C. A.; Risley, E. A.; Nuss, G. W. Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs Proc. Soc. Exp. Biol. Med. 1962, 111, 544-552
95. Cocco, M. T.; Congiu, C.; Onnis, V.; Morelli, M.; Felipo, V.; Cauli, O. Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity Bioorg. Med. Chem. 2004, 12, 4169-4177
96. i during caffeine contractures in rabbit cardiac myocytes J. Physiol. 1992, 453, 591-608